Mar 28, 2014 by Max MacalusoAn Interview With Portola Pharmaceuticals CEO Bill LisMotley Fool analyst Max Macaluso discusses Portola Pharmaceuticals' pipeline and approach to research and development with CEO Bill Lis.
Mar 24, 2014 by Max Macaluso and Taylor MuckermanBetter Buy: CONSOL Energy vs. Gilead SciencesWe've collected the most popular companies among Fool.com readers and put them head-to-head in a good old-fashioned challenge we're calling The Motley Fool Better-Buy Tournament.
Mar 22, 2014 by Max Macaluso and Patrick MorrisBetter Buy: Gilead Sciences vs. Berkshire HathawayWe've collected the most popular companies amongst Fool.com readers and put them head-to-head in a good old-fashioned challenge we're calling The Motley Fool's Better Buy Tournament.
Mar 21, 2014 by Max Macaluso and Joel SouthBetter Buy: Enterprise Products Partners vs. AmgenWe've collected the most popular companies amongst Fool.com readers and put them head-to-head in a good old-fashioned challenge we're calling The Motley Fool Better-Buy Tournament.
Mar 20, 2014 by Max MacalusoRanking Big Pharma's Top Drugs of 2013Ranking the pharma industry's three biggest winners of 2013.
Mar 18, 2014 by Max Macaluso and Mark ReethBetter Buy: Netflix vs. Gilead SciencesWe've collected the most popular companies amongst Fool.com readers and put them head-to-head in a good old-fashioned challenge we're calling The Motley Fool Better-Buy Tournament.
Mar 16, 2014 by Max Macaluso3 Prescription Drugs You Didn't Know Come From MarijuanaA close look at three prescription drugs you probably didn't know come from one of the world's most controversial plants: cannabis.
Mar 7, 2014 by Max MacalusoThe Spark of Innovation at Vertex Pharmaceuticals IncorporatedMotley Fool analyst Max Macaluso discusses how Vertex Pharmaceutical's culture helped the company develop break-through medications with author Barry Werth.
Mar 3, 2014 by Max Macaluso4 Keys to Vertex Pharmaceuticals' SuccessMotley Fool analyst Max Macaluso discusses the keys to Vertex Pharmaceuticals' success with Barry Werth, author of "The Antidote: Inside the World of New Pharma."
Feb 27, 2014 by Max MacalusoAsk a Fool: What Is Your Foolish Opinion of Horizon Pharma?Here's one analyst's Foolish take on this explosive biotech stock.
Feb 27, 2014 by Max MacalusoFrom Startup to Billion-Dollar Biotech: An Inside Look at Vertex PharmaceuticalsAn interview with Barry Werth, author of "The Antidote: Inside the World of New Pharma."
Feb 14, 2014 by Max MacalusoWhy Novartis Is One of Today's Most Innovative CompaniesWhat makes Novartis stand out from the crowd?
Feb 13, 2014 by Max MacalusoMarijuana Stocks: A Real Investing Opportunity or Not Worth the Hype?There has been a lot of hype around marijuana stocks lately, but is this market too immature to invest in today?
Feb 11, 2014 by Max MacalusoDividend Stock To Watch Today: SanofiThis is why investors should get Sanofi on their watchlist.
Feb 10, 2014 by Max MacalusoBig Pharma Diversification: A Winning Model or Recipe for Disaster?Should big pharma companies stick to diversified business models, or should they double down on drug development?
Feb 4, 2014 by Max MacalusoMedicine and Gaming: The Surprising Link You (Probably) Don't Know AboutThe worlds of medicine and gaming aren't as far apart as you might think.
Feb 3, 2014 by Max MacalusoAstraZeneca Stock: 1 Red Light, 1 Green LightOne pro and one con for investors looking at AstraZeneca today.
Jan 31, 2014 by Max MacalusoCan Teva Rebound After This Rejection?Teva got some very bad news last week. Will the company be able to bounce back?
Jan 29, 2014 by Max MacalusoSanofi Stock: Will This Be a Big Pharma Winner in 2014?Could Sanofi's strategy help boost returns this year, despite its lackluster 2013?
Jan 29, 2014 by Max MacalusoEli Lilly Stock: 1 Red Light, 1 Green LightEli Lilly had a rough 2013, but the yield is attractive. Is this a good point to jump in?
